Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07243418

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

Dual-cohort, Single-arm, Exploratory Phase II Clinical Study of Hetrombopag for Primary/Secondary Prevention of Thrombocytopenia Induced by ADC Drugs in Breast Cancer

Sponsor: Fujian Cancer Hospital

Conditions Breast Cancer CTIT-Chemotherapy Induced Thrombocytopenia

Interventions herombopag olamine tablets

Updated 1 time since 2025 Last updated: Nov 19, 2025 Started: Nov 30, 2025 Primary completion: Nov 30, 2027 Completion: May 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07243418, this PHASE2 trial focuses on Breast Cancer and CTIT-Chemotherapy Induced Thrombocytopenia and remains actively recruiting participants. Sponsored by Fujian Cancer Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.